Eli Lilly and Company (NYSE:LLY)‘s stock had its “sell” rating reiterated by equities researchers at BMO Capital Markets in a research note issued on Wednesday. They currently have a $73.00 target price on the stock. BMO Capital Markets’ target price indicates a potential downside of 10.66% from the company’s current price.
Other equities analysts also recently issued reports about the company. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $88.00 price target on shares of Eli Lilly and in a research report on Sunday, May 21st. TheStreet downgraded Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research report on Wednesday, July 26th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, May 30th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $88.27.
Shares of Eli Lilly and (NYSE:LLY) traded down 1.25% during mid-day trading on Wednesday, reaching $80.69. The company’s stock had a trading volume of 3,923,992 shares. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72. The firm has a market cap of $85.13 billion, a PE ratio of 34.92 and a beta of 0.34. The firm’s 50 day moving average is $82.77 and its 200 day moving average is $81.92.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.86 earnings per share. On average, equities analysts anticipate that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at approximately $10,307,254,924.47. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the sale, the insider now directly owns 14,041 shares in the company, valued at $1,134,231.98. The disclosure for this sale can be found here. Over the last three months, insiders have sold 669,733 shares of company stock worth $55,845,287. Corporate insiders own 0.20% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after buying an additional 1,610,885 shares during the last quarter. BlackRock Inc. increased its position in Eli Lilly and by 2.1% in the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after buying an additional 1,323,259 shares during the period. State Street Corp increased its position in Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after buying an additional 651,424 shares during the period. Janus Henderson Group PLC increased its position in Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock valued at $769,774,000 after buying an additional 9,223,251 shares during the period. Finally, Geode Capital Management LLC increased its position in Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after buying an additional 708,597 shares during the period. 75.59% of the stock is currently owned by institutional investors and hedge funds.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
